JAK3-IN-1 NEW
| Price | $228 | $766 | $996 |
| Package | 5mg | 25mg | 50mg |
| Min. Order: | |
| Supply Ability: | 10g |
| Update Time: | 2024-11-18 |
Product Details
| Product Name: JAK3-IN-1 | CAS No.: 1805787-93-2 |
| Supply Ability: 10g | Release date: 2024/11/18 |
Product Introduction
Bioactivity
| Name | JAK3-IN-1 |
| Description | JAK3-IN-1 is a selective and orally active JAK3 inhibitor (IC50: 4.8 nM). JAK3-IN-1 displays over 180-fold more selective for JAK3 than JAK1 (IC50: 896 nM) and JAK2 (IC50: 1050 nM). |
| In vitro | JAK3-IN-1 most potently inhibits JAK3 and identified fms-related tyrosine kinase 3 (FLT3) and several tyrosine protein kinase (TEC)-family kinases as being potential off-targets. JAK3-IN-1 selectively inhibits the proliferation of JAK3-dependent Ba/F3 cells (IC50 = 69 nM) relative to other JAK-dependent Ba/F3 cells, for which there was no antiproliferative effect at concentrations below 3.0 μM. JAK3-IN-1 displays very low inhibition scores for other JAKs and wild-type (WT) EGFR, which is consistent with the over 180-fold higher IC50s against EGFRWT and TYK2 (IC50s =409 nM, > 10000 respectively). JAK3-IN-1 possesses over 165-fold higher IC50s for BTK or ITK (IC50s = 794 and 1070 nM respectively). JAK3-IN-1( 0-5 μM; 3 hours; BMDMs cells) treatment fullly inhibits IL-4 induced p-STAT6 at a concentration of 500 nM and only partially inhibits IFNβ-induced p-STAT1 at a concentration of 5.0 μM. Enzymatic assays using the Z'-lyte or LanthaScreen formats confirmed enzymatic inhibition of FLT3 (IC50 = 13 nM), TTK protein kinase (TTK, IC50 = 49 nM), BLK proto-oncogene (BLK, IC50 = 157 nM) and tyrosine protein kinase TXK (TXK, IC50 = 36 nM) [1]. |
| In vivo | The numbers of B or T lymphocytes in the tumor-bearing lungs and spleens of treated mice is not affected, after oral administration with JAK3-IN-1(Compound 9) (75 mpk, QD) for 8 days, however, the number of NK cells is reduced. JAK3-IN-1 displays reasonable pharmacokinetic properties, with moderate T1/2 of 1.4 h, area under the curve (AUC) value of 795 ng*hr/mL following a 10 mg/Kg oral dose and good oral bioavailability of 66% [1]. |
| Storage | store at low temperature | Powder: -20°C for 3 years | In solvent: -80°C for 1 year | Shipping with blue ice. |
| Solubility Information | DMSO : 47 mg/mL (92.52 mM) |
| Keywords | JAK-3-IN-1 | JAK3 IN 1 | JAK3IN1 | JAK3-IN-1 |
Company Profile Introduction
Target Molecule Corp. (TargetMol) is a global high-tech enterprise, headquartered in Boston, MA, specializing in chemical and biological research product and service to meet the research needs of global customers.
TargetMol has evolved into one of the biggest global compound library and small molecule suppliers and a customer based on 40+ countries. TargetMol offers over 80 types of compound libraries and a wide range of high-quality research chemicals including inhibitors, activator, natural compounds, peptides, inhibitory antibodies, and novel life-science kits, for laboratory and scientific use. Besides, virtual screening service is also available for customers who would like to conduct the computer-aided drug discovery.
You may like
Recommended supplier
| Product name | Price | Suppliers | Update time | |
|---|---|---|---|---|
| $247.00/1mg |
VIP5Y
|
TargetMol Chemicals Inc.
|
2024-11-19 | |
| $2500.00/100mg |
VIP1Y
|
TargetMol Chemicals Inc.
|
2024-11-19 | |
| $0.00/10mg |
VIP1Y
|
Hubei Chuchang Biotech Co., Ltd.
|
2024-10-29 |
United States- Since: 2011-01-07
- Address: 36?Washington?Street, Wellesley?Hills
INQUIRY